Awards & Advancement

Biogen appoints Anirvan Ghosh SVP, Research and Early Development

Friday, March 17, 2017

Biogen appointed Anirvan Ghosh, Ph.D., as senior vice president, Research and Early Development (RED). Dr. Ghosh will lead Biogen’s RED organization in the discovery and development of drug candidates from idea through proof of concept. He will report to Michael Ehlers, M.D., Ph.D., executive vice president, Head of Research and Development. Dr. Ghosh will begin his service at Biogen in April.

[Read More]

GI Dynamics adds Galvao and Cummings to Scientific Advisory Board

Monday, March 13, 2017

GI Dynamics, a medical device company that has commercialized EndoBarrier in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced additional members of the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Manoel Galvao Neto, M.D., and David E. Cummings, M.D., have joined the GI Dynamics SAB.

[Read More]

Bristol-Myers Squibb appoints Dr. Thomas J. Lynch, Jr., EVP and CSO

Thursday, March 9, 2017

Bristol-Myers Squibb has appointed Dr. Thomas J. Lynch, Jr., executive vice president and chief scientific officer, effective March 16, 2017. He succeeds Dr. Francis Cuss, who will retire from the company. Dr. Cuss will serve as an advisor to the company for the next three months to ensure a seamless transition. In connection with today’s announcement, Dr. Lynch will step down from the Board of Directors of Bristol-Myers Squibb, effective March 15, 2017.

[Read More]

Epizyme President of Research and Chief Scientific Officer Robert Copeland to retire

Thursday, March 9, 2017

Epizyme, a clinical-stage biopharmaceutical company creating novel epigenetic therapies, has announced that President of Research and Chief Scientific Officer Robert A. Copeland, Ph.D., will be retiring from Epizyme in the second quarter of 2017 to pursue advisory and other opportunities within the industry. Dr. Copeland has served in his role since 2008, and will remain a key advisor to Epizyme following his transition. The company is executing plans for continued growth of its investigational pipeline, with plans to name its next development candidate in 2017 as part of its goal of delivering three new candidates into the clinic by 2020.

[Read More]